BRIEF published on 12/11/2025 at 07:05, 8 days 7 hours ago BioVersys lance un essai de phase 3 pour le BV100 et fait le point sur ses progrès commerciaux. Introduction En Bourse BioVersys Résistance Aux Médicaments BV100 Phase 3 Recherche Antibactérienne
BRIEF published on 12/11/2025 at 07:05, 8 days 7 hours ago BioVersys Initiates Phase 3 Trial for BV100 and Updates Business Progress IPO Drug Resistance BioVersys BV100 Phase 3 Antibacterial Research
PRESS RELEASE published on 12/11/2025 at 07:00, 8 days 7 hours ago BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update BioVersys AG initiates BV100 Phase 3 study for ventilator-associated bacterial pneumonia, achieving significant milestones in 2025 and upcoming key events in 2026 Clinical Trials Biopharmaceutical BioVersys AG BV100 Phase 3 Ventilator Associated Bacterial Pneumonia
BRIEF published on 11/10/2025 at 07:05, 1 month 9 days ago L'étude de phase 2B BV100 de BioVersys est prévue pour l'Asie Essai De Phase 2b Résistance Aux Médicaments BioVersys BV100 Financement Wellcome Réseau ADVANCE-ID
BRIEF published on 11/10/2025 at 07:05, 1 month 9 days ago BioVersys' BV100 Phase 2B Study Set for Asia Phase 2B Trial Drug Resistance BioVersys BV100 Wellcome Funding ADVANCE-ID Network
PRESS RELEASE published on 11/10/2025 at 07:00, 1 month 9 days ago BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. BioVersys AG leads Phase 2 trial for innovative antibacterial product BV100 Phase 2b Clinical Trial BV100 BioVersys Wellcome Funded Trial Network
BRIEF published on 11/06/2025 at 07:05, 1 month 13 days ago BioVersys Advances BV100 Clinical Trials in China Clinical Trials BV100 BioVersys MDR Bacteria Acinetobacter
BRIEF published on 11/06/2025 at 07:05, 1 month 13 days ago BioVersys fait progresser les essais cliniques du BV100 en Chine Essais Cliniques BV100 BioVersys Bactéries Multirésistantes Acinetobacter
PRESS RELEASE published on 11/06/2025 at 07:00, 1 month 13 days ago Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA BioVersys announces the dosing of the first subject in a Phase 1 clinical trial with BV100 in China. BV100 targets MDR hospital infections caused by Acinetobacter baumannii Phase 1 Clinical Trial BV100 BioVersys MDR Bacteria Acinetobacter Baumannii
BRIEF published on 11/05/2025 at 07:05, 1 month 14 days ago BioVersys to Present at Stifel 2025 Annual Healthcare Conference New York City Healthcare Conference Clinical Developments BioVersys Multi-drug Resistant Bacteria
Published on 12/19/2025 at 14:40, 5 minutes ago Northern Superior Announces Closing of the Arrangement
Published on 12/19/2025 at 13:30, 1 hour 15 minutes ago Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF
Published on 12/19/2025 at 13:30, 1 hour 15 minutes ago DataMetrex Announces Closing of Yuzu Payment Processing Solution Acquisition
Published on 12/19/2025 at 13:30, 1 hour 15 minutes ago Sterling Metals Provides Year End Update to Stakeholders
Published on 12/19/2025 at 13:05, 1 hour 40 minutes ago Roxmore Resources Begins Trading on the OTCQX Best Market in the United States
Published on 12/19/2025 at 14:05, 40 minutes ago ETHGas Debuts Ethereum's Blockspace Futures Market with $800m of Commitments and $12m Seed Round Led by Polychain Capital
Published on 12/19/2025 at 14:00, 45 minutes ago EQS-Adhoc: EVAN Group plc: Delisting of Bond has been resolved
Published on 12/19/2025 at 13:31, 1 hour 14 minutes ago North Peak Confirms Historic Waste Rock Pile Mineralisation with Sonic Drilling and Completion of 2025 Reverse Circulation Exploration Drilling Program at Prospect Mountain, Nevada
Published on 12/19/2025 at 13:18, 1 hour 27 minutes ago Gennaker offshore wind farm obtains construction and operations permit
Published on 12/19/2025 at 13:15, 1 hour 30 minutes ago PATRIMOINE ET COMMERCE: Descriptif du programme de rachat d’actions autorisé par l’assemblée générale mixte des actionnaires du 12 juin 2025 et lancement d’un programme de rachat d’actions
Published on 12/19/2025 at 08:30, 6 hours 15 minutes ago Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 08:30, 6 hours 15 minutes ago Réduction du capital par voie d’annulation d’actions propres
Published on 12/19/2025 at 07:00, 7 hours 45 minutes ago EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 7 hours 45 minutes ago EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION
Published on 12/18/2025 at 18:30, 20 hours 15 minutes ago Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
